First, let me address the issue of R&D funding.
Increasingly, I think, Canada has seen a core capacity built, thanks to public research investment in this country. It was well needed, and we need to continue to build it on an ongoing basis; we cannot rest on our laurels, but we need to continue to foster that.
What has happened from that investment, in our case, is that we now have well over 500 companies established in this country conducting research related to all fields in the biotechnology sector who, for the most part, are small entrepreneurial companies leveraging investment from international investors and small amounts of investment from within the Canadian capital community—although, as I mentioned, it's very small. We're now at a point in time where there are some serious opportunities and decisions ahead as to how we now galvanize our investment dynamic for research in this country to attract the best of what we can do internationally. We need international dollars, there are no two ways about that.
Quebec, particularly, has been one of the core regions in this country that have developed the sector incredibly successfully. Actually, I was with my colleague from BIOQuébec over the weekend. The dynamic there right now, like in the rest of the country, is again very uncertain because of the investment climate that's needed.
So from our position, we very much see our relationship as a partnership between public dollars and what they can leverage to the table in terms of private dollars.